
TUESDAY, Sept. 6, 2022 (HealthDay News) – A U.S. Food and Drug Administration panel will once again consider approval for an experimental drug for ALS, a rare second review for a disease that has no cure. The same panel that will meet Wednesday voted last March not to approve the drug for the deadly neurodegenerative… read on > read on >